AtriCure, Inc. - צמיחת מכירות משנה לשנה (TTM) ATRC

AtriCure, Inc. (ATRC) revenues depend on insurance reimbursements and the adoption of its technologies by physicians. The current year-over-year (TTM) revenue growth rate on the GURU.Markets chart confirms market confidence, with the latest parameter standing at 13.70. The business is protected by cryoablation patents and strict FDA oversight. Meanwhile, AtriCure, Inc. (ATRC) maintains in-house production of key instruments, outsourcing only standard components to external partners.
AtriCure, Inc. - פילוחים אנליטיים ומדדי מפתח (ATRC)

For AtriCure, Inc. (ATRC), whose dominance in atrial fibrillation surgery is cemented by the implementation of the gold standard in ablation devices, this indicator reflects the pace of revenue expansion. Analyzing this LTM year-over-year sales volume chart, an investor sees a twelve-month rolling trend, which eliminates quarterly distortions and allows for an accurate assessment of the business's fundamental growth rate.